BioMed Realty Trust, Inc. (NYSE: BMR) a real estate investment trust focused on the life science industry has entered into an agreement to acquire Array BioPharma’s (Nasdaq: ARRY) approximately 150,000 square-foot, four-building campus in Boulder and 78,000 square-foot, two-building campus in Longmont. The transactions are $45.0 million for the Boulder campus and $20.8 million for [...]

• 100http://clsdf.com/2006/06/array-biopharma-pads-war-chest/Array+Biopharma+Pads+War+Chest2006-06-25+16%3A04%3A00admin

Array BioPharma, Inc. (Nasdaq: ARRY) initiated a Phase I clinical trial in the US for ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease. The compound will be evaluated in dose escalation studies in normal, healthy volunteers. MEK is a protein kinase that regulates both the biosynthesis of and response to a number [...]

• 93http://clsdf.com/2006/04/array-initiates-phase-i-clinical-trial/Array+Initiates+Phase+I+Clinical+Trial2006-04-26+19%3A38%3A00admin

Array BioPharma Inc. (Nasdaq: ARRY) and AstraZeneca AB selected a third compound for their small molecule MEK anti-cancer program, triggering a $1 million milestone payment from AstraZeneca to Array. The second compound was selected in January 2006, which also paid a $1 million milestone to Array. In December 2003, Array partnered the oncology portion of [...]

• 88View 1 Comment...http://clsdf.com/2006/04/array-biopharma-selects-third-compound/Array+BioPharma+Selects+Third+Compound2006-04-13+14%3A34%3A00admin